Do Quality-Adjusted Life-Years Discriminate Against the Elderly? An Empirical Analysis of Published Cost-Effectiveness Analyses
Journal of the American Geriatrics Society
Racial and ethnic differences in disease course Medicare expenditures for beneficiaries with dementia
Seminars in Arthritis and Rheumatism
Increasing uptake through collaboration in the development of core outcome sets: Lessons learned at OMERACT 2023
Value in Health
It's time to reconsider the three percent discount rate.
Health Affairs Forefront
Are We Valuing Prescription Drugs Appropriately?
Pharmacoeconomics
Incorporating real option value in valuing innovation: a way forward
Future Oncology
Beyond conventional clinical value: estimating the impact of accelerated approvals on therapeutic bridging between innovative cancer therapies in three solid tumors.
Health Policy Open
Variation in Medicaid and commercial coverage of cell and gene therapies
Journal of Alzheimer's Disease
Life-Sustaining Treatments Among Medicare Beneficiaries with and without Dementia at the End of Life
